MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study [Yahoo! Finance]
MBX Biosciences, Inc. (MBX)
Company Research
Source: Yahoo! Finance
On Monday, the company announced that once-weekly canvuparatide achieved the primary endpoint with statistical significance at Week 12 in its Phase 2 Avail trial. The trial demonstrated positive 6-month results from the open-label extension (OLE) in adult patients with chronic hypoparathyroidism All patients (n=64) completed the 12-week study, and 94% of patients elected to enroll in the OLE. In the 12-week randomized portion of the trial, 63% of canvuparatide-treated patients met the prespecified primary composite endpoint with zero contribution from PRN rescue therapy compared with 31% in placebo-treated patients. Also Read: Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market In the OLE, 79% of patients receiving once-weekly canvuparatide achieved responder status at 6 months Responders were defined as patients who maintained serum calcium levels in the normal range (8.2–10.6 mg/dL) and independence from conventional therapy. MBX is preparing to initiate a
Show less
Read more
Impact Snapshot
Event Time:
MBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBX alerts
High impacting MBX Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
MBX
News
- MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM Exit - What's Changed [Yahoo! Finance]Yahoo! Finance
- MBX Biosciences (NASDAQ:MBX) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "sell" rating and a $18.00 price target on the stock.MarketBeat
- Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus [Yahoo! Finance]Yahoo! Finance
- How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% [Yahoo! Finance]Yahoo! Finance
- This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones [Yahoo! Finance]Yahoo! Finance
MBX
Earnings
- 11/6/25 - Beat
MBX
Sec Filings
- 11/25/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- MBX's page on the SEC website